Moberg Pharma Logo

Moberg Pharma

ISIN: SE0013121340 | Ticker: MOB | LEI: 549300XFXK7DVGDRP410
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Sweden

About Moberg Pharma

Company Description

s of April 2019, Moberg Pharma focuses on the commercialization of its clinical pipeline with a combined peak sales potential estimated at USD 350–700 million. MOB-015 is a next generation nail fungus treatment, and BUPI is a novel treatment for oral pain relief in association with inflammation and ulceration of the oral mucous membranes (oral mucositis or OM), a serious complication of cancer treatment. Both drugs have demonstrated strong clinical results which indicate that they have the potential to become market leaders in their respective niches.

Moberg Pharma has secured commercialization partners for MOB-015 in Europe, Japan, Canada, Israel and the Republic of Korea. MOB-015 has recently been evaluated over 52 weeks in two randomized, multicenter, controlled Phase 3 studies, including in total more than 800 patients in North America and Europe. The primary endpoint was met in both studies, the proportion of patients achieving complete cure of their target nail.

Year founded



Gustavslundsvägen 42, 16751 Bromma – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2021 01.01.2022 01.01.2023
Assets N/A 450,889,000.00 564,423,000.00
Noncurrent Assets N/A 346,234,000.00 436,663,000.00
Office Equipment N/A 0.00 0.00
Intangible Assets Other Than Goodwill N/A 327,042,000.00 408,104,000.00
Intangible Assets Under Development N/A 327,042,000.00 408,104,000.00
Deferred Tax Assets N/A 14,673,000.00 22,575,000.00
Other Noncurrent Assets N/A 19,192,000.00 28,559,000.00
Current Assets N/A 104,655,000.00 127,760,000.00
Current Trade Receivables N/A 474,000.00 383,000.00
Current Prepayments N/A 862,000.00 772,000.00
Cash and cash equivalents 29,285,000.00 102,655,000.00 125,550,000.00
Equity And Liabilities N/A 450,889,000.00 564,423,000.00
Equity 395,577,000.00 434,051,000.00 533,584,000.00
Issued Capital N/A 4,405,000.00 9,827,000.00
Retained Earnings N/A -301,730,000.00 -317,440,000.00
Additional Paidin Capital N/A 731,376,000.00 841,197,000.00
Equity Attributable To Owners Of Parent N/A 434,051,000.00 533,584,000.00
Liabilities N/A 16,838,000.00 30,839,000.00
Noncurrent Liabilities N/A 1,300,000.00 4,053,000.00
Other Noncurrent Liabilities N/A 65,000.00 65,000.00
Current Liabilities N/A 15,538,000.00 26,786,000.00
Accruals Classified As Current N/A 6,565,000.00 6,544,000.00
Other Current Liabilities N/A 970,000.00 1,017,000.00
Line item in (sek) 01.01.2021/
Revenue From Contracts With Customers 0.00 207,000.00
Other Income 2,227,000.00 1,815,000.00
Profit Loss From Operating Activities -19,730,000.00 -20,226,000.00
Finance Income 0.00 786,000.00
Finance Costs 240,000.00 72,000.00
Profit Loss Before Tax -19,970,000.00 -19,512,000.00
Income Tax Expense Continuing Operations -3,748,000.00 -3,802,000.00
Profit Loss From Continuing Operations -16,222,000.00 -15,710,000.00
Profit Loss From Discontinued Operations 23,589,000.00 0.00
Profit (loss) 7,367,000.00 -15,710,000.00
Profit Loss Attributable To Owners Of Parent 7,492,000.00 -15,710,000.00
Profit Loss Attributable To Noncontrolling Interests -125,000.00 0.00
Line item in (sek) 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A 7,367,000.00 -15,710,000.00
Adjustments For Income Tax Expense N/A 0.00 0.00
Adjustments For Depreciation And Amortisation Expense N/A 2,584,000.00 2,582,000.00
Adjustments For Sharebased Payments N/A 631,000.00 1,458,000.00
Adjustments For Fair Value Gains Losses N/A 0.00 0.00
Cash Flows From Used In Operations N/A -15,296,000.00 -16,842,000.00
Interest Paid Classified As Operating Activities N/A 240,000.00 71,000.00
Interest Received Classified As Operating Activities N/A 0.00 0.00
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A 9,999,000.00 0.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 31,309,000.00 68,072,000.00
Cash Flows From Used In Investing Activities N/A -41,308,000.00 -68,072,000.00
Proceeds From Issuing Shares N/A 133,438,000.00 109,682,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 3,464,000.00 1,873,000.00
Cash Flows From Used In Financing Activities N/A 129,974,000.00 107,809,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A 73,370,000.00 22,895,000.00
Cash and cash equivalents 29,285,000.00 102,655,000.00 125,550,000.00

Please note that some sums might not add up.

Filings & Publications


Consolidated Report
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
11.11.21 Mark Beveridge Other Buy SEK 17,730.00
10.11.21 Mark Beveridge Other Buy SEK 17,310.00
09.11.21 Mark Beveridge Other Buy SEK 29,800.00
10.02.21 Cindy Wong Other Buy SEK 31,675.00
09.02.21 Cindy Wong Other Buy SEK 30,800.00

Capital markets information






Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences





Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.